National Board of Examinations

Question Paper Name :	DNB General Medicine Paper3
Subject Name :	DNB General Medicine Paper3
Creation Date :	2024-10-19 17:56:25
Duration :	180
Total Marks :	100
Display Marks:	No
Share Answer Key With Delivery Engine :	No
Actual Answer Key :	No

DNB General Medicine Paper3

Group Number :	1
Group Id :	3271872742
Group Maximum Duration :	0
Group Minimum Duration :	180
Show Attended Group? :	No
Edit Attended Group? :	No
Break time :	0
Group Marks :	100

DNB General Medicine Paper3

Section Id :	3271872745
Section Number :	1
Section type :	Offline
Mandatory or Optional :	Mandatory
Number of Questions :	10
Number of Questions to be attempted :	10
Section Marks :	100
Maximum Instruction Time :	0
Sub-Section Number :	1
Sub-Section Id :	3271872749
Question Shuffling Allowed :	No

Question Number : 1 Question Id : 32718728704 Question Type : SUBJECTIVE Consider As Subjective : Yes Correct Marks : 10

Question Number	Answer to be attempted within	Question Number	Answer to be attempted within
Q. 1	Page 1-5	Q. 6	Page 26-30
Q. 2	Page 6-10	Q. 7	Page 31-35
Q. 3	Page 11-15	Q. 8	Page 36-40
Q. 4	Page 16-20	Q. 9	Page 41-45
Q. 5	Page 21-25	Q. 10	Page 46-50

Please write your answers in the answer booklet within the allotted pages as follows:-

1. a) Enumerate the causes of secondary Hypertension. [3]

b) Outline the approach to a patient with resistant HTN. [7]

Question Number : 2 Question Id : 32718728705 Question Type : SUBJECTIVE Consider As Subjective : Yes

Correct Marks : 10

a) Define asymptomatic LV dysfunction (ASLVD) and its pathogenesis. [1+3]

b) Outline the protocol for its screening. [3]

c) Discuss the role of SGLT2 inhibitors and devices therapy in ASLVD. [3]

Question Number : 3 Question Id : 32718728706 Question Type : SUBJECTIVE Consider As Subjective : Yes

Correct Marks : 10

a) Discuss the pathophysiology and diagnosis of Cytomegalovirus infection. [3+2]

b) Describe the treatment of CMV disease in an immunocompromised host. [5]

Question Number : 4 Question Id : 32718728707 Question Type : SUBJECTIVE Consider As Subjective : Yes

Correct Marks : 10

a) Define Multi-drug resistant and XDR (extensive drug resistant) Tuberculosis. [2]

b) Outline the risk factors for Drug resistant-TB (DR-TB). [3]

c) Discuss the integrated diagnosis of DR-TB. [3]

d) Write briefly about Bedaquiline. [2]

Question Number : 5 Question Id : 32718728708 Question Type : SUBJECTIVE Consider As Subjective : Yes

Correct Marks : 10

a) Iatrogenic injuries during Percutaneous Coronary Intervention. [5]

b) Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. [5]

Question Number : 6 Question Id : 32718728709 Question Type : SUBJECTIVE Consider As Subjective : Yes

Correct Marks : 10

a) Discuss the approach to a patient with Pancytopenia. [5]

b) Discuss the management of Aplastic Anaemia. [5]

Question Number : 7 Question Id : 32718728710 Question Type : SUBJECTIVE Consider As Subjective : Yes

Correct Marks : 10

a) Management of Acute Ischemic Stroke. [5]

b) Outline the strategies to prevent recurrence of Ischemic Stroke. [5]

Question Number : 8 Question Id : 32718728711 Question Type : SUBJECTIVE Consider As Subjective : Yes

Correct Marks : 10

Discuss the clinical features, diagnosis and treatment of Graves' Disease. [4+2+4]

Question Number : 9 Question Id : 32718728712 Question Type : SUBJECTIVE Consider As Subjective : Yes

Correct Marks : 10

a) Discuss pathogenesis of inflammatory polyarthritis. [5]

b) Define Refractory Rheumatoid Arthritis and describe its management. [1+4]

Question Number : 10 Question Id : 32718728713 Question Type : SUBJECTIVE Consider As Subjective : Yes

Correct Marks : 10

a) Describe the etiology and diagnosis of renal tubular acidosis. [2+3]

b) Outline the approach to the treatment of renal tubular acidosis. [5]